Growing evidence have been also provided about the critical role of NOTCH1 in driving resistances to anti-CD20 antibodies and BCL2 inhibitors, providing a rationale for NOTCH1 targeting in high-risk CLL and RT patients [36]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.